The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
 
Nitya Prabhakar Raj
Research Funding - Novartis (Inst); Xencor (Inst)
 
Youyun Zheng
No Relationships to Disclose
 
Virginia Kelly
No Relationships to Disclose
 
Seth Katz
No Relationships to Disclose
 
Joanne F Chou
No Relationships to Disclose
 
Richard K. G. Do
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Dmitriy Zamarin
Employment - Acorda Therapeutics (I)
Consulting or Advisory Role - ACM Biolabs; Agenus; BioMed Valley Discoveries; Merck; PsiOxus Therapeutics; Synlogic; Tesaro; Trieza Therapeutics; Western Oncolytics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - I hold a patent regarding the use of recombinant Newcastle Disease Virus (NDV) for cancer therapy. (Inst)
Travel, Accommodations, Expenses - Roche
 
Charlotte Eielson Ariyan
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
Speakers' Bureau - Bristol-Myers Squibb
 
Brian R. Untch
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Anuradha Gopalan
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Illumina
 
Kelly Olino
No Relationships to Disclose
 
Neil Howard Segal
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; EMD Serono; Gritstone Bio; Horizon Pharma; IFM Therapeutics; Imugene; Kyn therapeutics; Merck; Pfizer; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology
Research Funding - Bristol-Myers Squibb; Incyte; MedImmune; Merck; Pfizer; Roche/Genentech
 
Diane Lauren Reidy
Honoraria - Novartis
Consulting or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Novartis